Skip to main content
PMC home page
Stem Cell Research & Therapy logoLink to Stem Cell Research & Therapy
. 2019 Nov 28;10:356. doi: 10.1186/s13287-019-1450-3

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

Raquel Cabrera-Pérez 1,2,✉, Marta Monguió-Tortajada 3, Ana Gámez-Valero 3, Raquel Rojas-Márquez 1,4, Francesc Enric Borràs 3,5, Santiago Roura 6, Joaquim Vives 1,2,7,✉
PMCID: PMC6883559  PMID: 31779673

Abstract

Background

Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear.

Methods

Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested.

Results

Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC.

Conclusions

Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.

Keywords: Mesenchymal stromal cells, Bone marrow, Wharton’s jelly, Osteogenic differentiation, Bone regeneration

Background

The development of new treatments for bone-related diseases resulting from trauma or pathophysiological age-, sex- or infection-associated bone resorption has become a priority in the field of regenerative medicine [1–4]. In this context, autologous cell-based therapy has been presented as a promising approach to promote bone regeneration in both pre-clinical and clinical settings [5–8]. However, their clinical translation needs the delivery of safe and efficacious products, which can be largely hampered by age and co-morbidities of the cell donor [9–13]. In contrast, allogeneic off-the-shelf cell products derived from healthy and immune-compatible donors are very attractive since they are immediately available and provide a high number of cells [14, 15].

Multipotent mesenchymal stromal cells (MSC) constitute a heterogeneous population of non-haematopoietic multipotent cells which can be isolated from a variety of human body sources [3, 16, 17]. In particular, MSC have a fibroblast-like appearance, plastic adherence, the ability to differentiate into tissues of mesodermal lineages (adipocytes, chondrocytes and osteocytes) and a specific cell surface expression pattern, according to the minimal criteria established by the International Society for Cell and Gene Therapy (ISCT) [18]. Of note, a couple of MSC-based products have already received marketing approval [19], whereas most developments are still in clinical evaluation, including MSC-based tissue engineering products (EudraCT Nos. 2010-024041-78, 2010-023998-18, 2010-023999-12 and 2013-005025-23) under development in our laboratory [20].

Bone marrow (BM) has become the most used source of MSC in the orthopaedic field because of its intrinsic osteogenic differentiation potential, but alternative sources are garnering attraction. These include Wharton’s jelly (WJ), which is the connective tissue surrounding the human umbilical cord and is advantageous for cell collection since its isolation is not painful, does not require invasive procedures and does not raise major ethical concerns [21]. Accordingly, we reported the feasibility of expanding clinical-grade WJ-MSC from samples typically discarded from public cord blood banking programmes [22]. Moreover, in contrast to adult BM-MSC, WJ-MSC are expected to be more primitive, proliferative and immunosuppressive cells, particularly for the lack of HLA-DR antigens [23–26]. Nevertheless, the osteogenic capacity of WJ-MSC remains under scrutiny.

Osteogenic differentiation of mesenchymal precursors and bone regeneration are extremely complex processes regulated by the interaction of different signalling pathways including TGFβ/BMP, MAPK, Wnt, Hedgehog, Notch and AKT/mTOR [27]. Among them, the TGFβ/BMP pathway plays the major role in the regulation of osteoblast lineage-specific differentiation, bone induction, maintenance and repair and constitutes a promising target for the treatment of bone diseases [28–30]. Up to date, about 60 TGFβ family proteins have been identified so far, being TGFβ1 and BMP2 ligands the most widely investigated due to their positive role in bone formation in vivo [31, 32]. However, while BMP proteins have been demonstrated to induce the expression of MSC differentiation factors (such as DLX5 and RUNX2) [33, 34], several in vitro studies have described a negative impact of TGFβ1 on the terminal differentiation of osteoblast precursors [34–36].

Despite several reports investigating the osteogenic capabilities of BM- and WJ-MSC have been published to date, it is still difficult to integrate existing data due to heterogeneity in MSC isolation and culture procedures. In the present study, we aimed to provide homogeneous and comparative data regarding the ability of BM- and WJ-MSC to differentiate towards the osteogenic lineage by means of cytological staining and molecular and proteomic analysis. Moreover, we evaluated a variety of strategies based on the modulation of the TGFβ/BMP pathway and the use of the BM-MSC secretome to enhance osteogenesis in WJ-MSC and emulate BM-MSC osteogenic commitment.

Methods

Cell culture

BM-MSC (n = 3) and WJ-MSC (n = 3) (passage 3–5) were isolated according to ‘Good Manufacturing Practice for Advanced Therapy Medicinal Products’ (GMP for ATMPs, European Commission Guidelines of 2017.11.22) and further expanded in Dulbecco’s modified Eagle’s medium (DMEM) (31885-023; Gibco) containing 2 mM glutamine and supplemented with 10% human serum B (hSerB)—‘expansion medium’ [37, 38]. All cell cultures were maintained at 37 °C and 5% CO2 in humidified incubators, and media were changed every 3–4 days. Cell number and viability were determined by the haemocytometer-based trypan blue dye exclusion assay.

Phenotype assessment

Immunophenotypic characterisation of MSC was performed using the following antibodies: mouse anti-human CD45-fluorescein isothiocyanate (CD45-FITC) (Clone HI30; 555482; BD Pharmingen), anti-human CD105-phycoerythrin (CD105-PE) (Clone 43A4E1; 130-117-696; Miltenyi Biotec), anti-human HLA-DR-FITC (Clone L243; 347363; BD Biosciences), anti-human CD90-PE (Clone F15-42-1-5; IM1840U; Beckman Coulter), anti-human CD31-FITC (Clone WM59; 555445; BD Pharmingen) and anti-human CD73-PE (Clone AD2; 550257; BD Pharmingen). Cells were stained for 15 min at room temperature (RT), washed and re-suspended in phosphate-buffered saline (PBS) (14190-094; Gibco) as described elsewhere [38]. Acquisition and data analysis were performed using a FACSCalibur cytometer and the CellQuest Pro software (Becton Dickinson), respectively.

Osteogenic differentiation assays

BM-MSC and WJ-MSC (passage 3–5) were seeded until 70–80% confluence (104 and 2 × 104 cells/cm2, respectively). ‘Differentiation media’ composed of the StemPro osteogenesis differentiation kit (A1007201; Gibco) supplemented with 100 units/mL of penicillin and 100 μg/mL streptomycin (Penicillin-Streptomycin; P4458; Sigma-Aldrich) was used for the osteogenic induction in vitro. Alkaline phosphatase (ALP) (B5655; Sigma-Aldrich) and alizarin red (AR) (2003999; Merck Millipore) staining were finally carried out to assess cell differentiation.

Gene expression assays

Total RNA was purified from cell cultures using the RNeasy Plus Mini Kit (74134; Qiagen) according to the manufacturer’s instructions, quantified using NanoDrop Lite (Thermo Scientific), and electrophoresed in 1% agarose gels to confirm integrity and purity. cDNA synthesis was then performed by reverse-transcription PCR (RT-PCR) using the High-Capacity cDNA Reverse Transcription Kit (4368814; Thermo Fisher Scientific) according to the manufacturer’s instructions. cDNA was finally amplified by quantitative real-time PCR (qRT-PCR) using the TaqMan gene expression assays listed in Table 1. In all cases, target gene expression was referred to GAPDH expression by using the 2−ΔCt method.

Table 1.

TaqMan gene expression assay ID

Gene Assay ID
MSX2 Hs00741177_m1
DLX5 Hs01573641_mH
RUNX2 Hs01047973_m1
SP7 Hs05049492_s1
ALPL Hs01029144_m1
TFGβ1 Hs00998133_m1
BGLAP Hs01587814_g1
COL1A2 Hs01028970_m1
GAPDH Hs02786624_g1
Open in a new tab

Inhibition/activation of TGFβ/BMP2 signalling pathways

WJ-MSC (passage 4) were seeded at a cell density of 2 × 104 cells/cm2. Inhibition of the TGFβ signalling pathway was carried out by addition of galunisertib (LY2157299) (sc-391123; Santa Cruz Biotechnology) to the osteogenic differentiation media at a final concentration of 10 μM. For BMP2 pathway stimulation, human recombinant BMP2 (SRP6155; Sigma-Aldrich) and/or tanshinone IIA (sc-200932; Santa Cruz Biotechnology) were added to a final concentration of 100 ng/mL and 5 μM, respectively. All compounds were added immediately after every media change after 1 week of in vitro osteogenic induction with differentiation media.

Extracellular vesicle isolation and characterisation

To avoid sample contamination with exogenous extracellular vesicles (EVs), cells were cultured in EV-depleted media. For EV depletion, 2× differentiation media was ultra-centrifuged at 100,000 × g for ≥16 h and diluted with StemPro Basal Media (A10069-01; Gibco) to 1× working concentration.

Supernatants derived from undifferentiated BM-MSC and WJ-MSC (passage 3–5) or from BM-MSC under osteogenic differentiation (passage 3–5) were collected at weeks 0, 1, 2 and 3, and were sequentially centrifuged at 400 × g for 5 min and at 2000 × g for 10 min to exclude cells and cell debris. Conditioned medium (CM) was then concentrated by 100-kDa ultrafiltration using Amicon Ultra (UFC910024; Millipore) at 2000 × g for 35 min, obtaining typically 250 μL of concentrated CM (CCM). EVs were isolated by size exclusion chromatography (SEC) as previously reported [39]. Protein elution was checked by reading absorbance at 280 nm using NanoDrop (Thermo Scientific).

The presence of EVs in the SEC fractions was determined according to the presence of tetraspanins by bead-based flow cytometry [39]. Briefly, EVs were coupled to 4-μm aldehyde/sulphate-latex microspheres (A37304; Invitrogen) for 15 min at RT and blocked in BCB buffer (PBS supplemented with 0.1% BSA (A4503) and 0.01% NaN3 (S8032); Sigma-Aldrich) on overnight rotation. EV-coated beads were spun down at 2000 × g for 10 min, washed with BCB buffer and re-suspended in PBS. EV-coated beads were labelled with the primary antibodies anti-CD9 (Clone VJ1/20) and anti-CD63 (Clone TEA3/18) (kindly provided by M. Yáñez-Mó (CBM-SO, IIS-IP, UAM, Madrid, Spain) and F. Sánchez-Madrid (Hospital Universitario de la Princesa, IIS-IP, UAM, CNIC, Madrid, Spain)) or the IgG isotype control (a637355; Abcam) and secondary antibody FITC-conjugated Goat F(ab′)2 Anti-Mouse IgG (1032-02; Bionova). EV-coupled beads were washed after each step with BCB buffer and centrifuged at 2000 × g for 10 min. Data was acquired in a FACSLyric flow cytometer (BD) and analysed by FlowJo v.X software (Tree Star).

SEC-EV-containing fractions were examined for EV size and morphology by cryo-electron microscopy (cryo-EM). Vitrified specimens were prepared by placing 3 μL of a sample on a Quantifoil® 1.2/1.3 TEM grid, blotted to a thin film and plunged into liquid ethane-N2(l) in the Leica EM CPC cryoworkstation (Leica). The grids were transferred to a 626 Gatan cryoholder and maintained at −179 °C. Samples were analysed with a Jeol JEM-2011 transmission electron microscope (Jeol) operating at an accelerating voltage of 200 kV. Images were recorded on a Gatan UltraScan 2000 cooled charge-coupled device (CCD) camera with the DigitalMicrograph software package (Gatan).

Proteomic analysis

The protein content of EV-enriched fractions was analysed by liquid chromatography followed by mass spectrometry (LC-MS/MS) on Orbitrap XL (Thermo Fisher) for three independent undifferentiated cultures for each MSC type. Data was searched against the Swiss-Prot human database (downloaded in August 2016), using the search algorithm Mascot v2.5.1. Only peptides showing a false discovery rate (FDR) lower than 5% were retained. Proteins identified with at least two unique peptides and found in all three samples were considered for further analysis.

The obtained proteomic profile for our samples was compared with previous studies compiled in EV-specific databases EVpedia [40], ExoCarta [41] and Vesiclepedia [42].

Data analysis

Statistical analysis was performed with the GraphPad Prism 6 software (GraphPad Software, Inc.). Descriptive data were expressed as mean ± standard deviation (SD). Multiple t tests were used for investigating differences between BM- and WJ-MSC at different time points along the osteogenic differentiation. Statistical significance was set at *p < 0.05 and **p < 0.01.

Results

WJ-MSC exhibit delayed osteogenic induction compared with BM-MSC

BM-MSC and WJ-MSC were highly positive for CD73, CD90 and CD105 and negative for CD31, CD45 and HLA-DR expression according to the ISCT criteria (Additional file 1).

The osteogenic differentiation of BM-MSC and WJ-MSC cultures were assessed by alkaline phosphatase (ALP) and alizarin red (AR) staining. All BM-MSC and WJ-MSC cell lines showed osteogenic potential in vitro after osteogenic induction with specific differentiation media. However, a delay in osteogenesis was observed in WJ-MSC compared to BM-MSC. In particular, as shown in Fig. 1a, most of the cells in BM-MSC cultures displayed a marked baseline activity of the osteogenic marker ALP. In contrast, in WJ-MSC cultures, only few cells exhibited ALP activity even at week 5. Regarding the results obtained for AR staining, calcium depositions were clearly visible in BM-MSC cultures at week 3. However, 5 weeks were required in order to obtain similar results in WJ-MSC (Fig. 1b).

Fig. 1.

Fig. 1

Open in a new tab

Differences in timing for osteogenic differentiation in BM-MSC and WJ-MSC cultures. Alkaline phosphatase (a) and alizarin red (b) staining at indicated times. N = 3 for both MSC types. Scale bars: 100 μm

BM-MSC show increased expression of osteogenic markers compared to WJ-MSC

We further analysed the delayed osteogenesis in WJ-MSC cultures. For that purpose, we comparatively assessed the time-course expression of key osteogenic genes implicated in MSC differentiation. Interestingly, we found some significant differences along both BM- and WJ-MSC osteogenic differentiation. Regarding osteogenic transcription factors (Fig. 2a), BM-MSC showed a progressive increase in DLX5, RUNX2 and SP7 expression. In contrast, in WJ-MSC, DLX5 expression was gradually decreased and SP7 levels exhibited an increment from week 2 to 5. Additional differences were observed in MSX2. Remarkably, a steady increase of MSX2 expression was observed up to week 5 in WJ-MSC, whereas no changes in MSX2 expression were detected in BM-MSC.

Fig. 2.

Fig. 2

Open in a new tab

Gene expression profiles of the main markers involved in osteogenic differentiation. Expression levels of osteogenic transcription factors (a) and early/late osteogenic markers (b). Bars represent mean ± SD. *p < 0.05 and **p < 0.01 (multiple t tests). N = 3 for each MSC type

Moreover, the expression patterns of main early and late osteogenic markers were comparatively assessed (Fig. 2b). In this sense, the early marker ALPL reached its maximum expression level during the first week in BM-MSC. However, in WJ-MSC, ALPL expression was reduced at this time compared to week 0 and started to increase again from the third week. The expression patterns of late osteogenic markers TGFβ1 and BGLAP were also different. In BM-MSC, TGFβ1 achieved the highest expression level at week 2 and BGLAP expression increased progressively. On the contrary, no changes were observed for these genes in WJ-MSC. In regard to COL1A2, similar expression patterns were obtained for both cell types, although expression in BM-MSC was twofold higher than that in WJ-MSC. Remarkably, the expression of RUNX2, DLX5, ALPL, TGFβ1, BGLAP and COL1A2 was promoted in BM-MSC even when they were in an undifferentiated stage. Taken together, these findings indicate a higher osteogenic differentiation commitment in BM-MSC.

Promotion of BMP2 signalling primes osteogenic differentiation of WJ-MSC

Subsequently, the role of TGFβ1 and BMP2 signalling pathways in the promotion of osteogenic differentiation of WJ-MSC was investigated. To prevent TGFβ activation, differentiation media was supplemented from week 1 to 3 with galunisertib. On the other hand, in order to stimulate osteogenic differentiation through the BMP2 signalling pathway, human recombinant BMP2 and/or the BMP activator tanshinone IIA were also added to the differentiation media (Fig. 3a).

Fig. 3.

Fig. 3

Open in a new tab

Modulation of the TGFβ/BMP signalling pathway to stimulate WJ-MSC osteogenic differentiation. a Scheme of the experimental design. From day 0 to week 1, cells were cultured in osteogenic differentiation media, which was supplemented from week 1 to 3 with galunisertib, BMP2 and/or tanshinone IIA. b Representative AR staining results obtained in passage 4 WJ-MSC after 2 weeks of culture in osteogenic media supplemented with galunisertib 10 μM, BMP2 100 ng/mL and tanshinone IIa 5 μM in different combinations. Scale bars: 100 μm

As shown in Fig. 3b, the inhibition of TGFβ1 signalling had no effect on WJ-MSC osteogenesis. Similarly, negative results in AR staining experiments were seen when BMP2 and tanshinone IIA were present alone or in combination with galunisertib. In contrast, when BMP2 and tanshinone IIA were added together, calcium depositions were clearly visible in WJ-MSC cultures after 3-week induction, emulating the behaviour of BM-MSC under standard osteogenic inducing conditions. This suggests the promotion of WJ-MSC osteogenic differentiation following stimulation of BMP2 signalling.

BM-MSC-conditioned media strongly enhances WJ-MSC osteogenic differentiation

The results obtained after the characterisation of the gene expression profiles of some of the main osteogenic markers explained, in part, the superior osteogenic potential presented by BM-MSC. However, with the aim of deepening in the elucidation of the increased osteogenic capacity shown by BM-MSC, the proteomic content associated with the isolated extracellular vesicles (EVs) from the supernatant of undifferentiated BM-MSC and WJ-MSC cultures was analysed. Proteomic analysis by LC-MS/MS allowed the identification of several EV markers, such as annexin A2, A5 and A6, glyceraldehyde-3-phosphate dehydrogenase and CD5L. As depicted in Fig. 4, 99 proteins were found in common between both types of cells. However, five osteogenic markers (namely COL6A1, COL6A2, PCOLCE, COL12A1 and COL6A3) were differentially overrepresented in BM-derived EVs compared to WJ-MSC EVs. This finding could contribute to the explanation of the higher osteogenic commitment observed in BM-MSC and suggested the possibility of using the BM-MSC secretome to prime osteogenesis in WJ-MSC.

Fig. 4.

Fig. 4

Open in a new tab

Osteogenic markers found in undifferentiated BM-MSC- and WJ-MSC-secreted EVs. Number of proteins found in extracellular vesicles (EVs) isolated by size exclusion chromatography (n = 3 different cell lines for BM-MSC and WJ-MSC). The osteogenic markers differentially overrepresented in BM-MSC EV samples are indicated. Results were obtained by LC-MS/MS, two peptides restricted, FDR<5%

To test the feasibility of this approach, conditioned media (CM) from BM-MSC cultures were obtained weekly up to week 3 of the osteogenic differentiation and processed by size exclusion chromatography to separate and purify fractions enriched in EVs or soluble proteins (Additional file 2). Once isolated, the EV or protein fractions were added to WJ-MSC differentiating cultures.

Monitoring of the osteogenic differentiation was performed by AR staining. Negative results were obtained in all cases after 2 weeks of media supplementation with either EVs or protein fractions (data not shown). However, after 3 weeks, calcium depositions were observed in all the WJ-MSC cultures supplemented with BM-secreted EVs and protein fractions purified from BM-MSC differentiating cultures at weeks 1, 2 and 3, while the secretome from undifferentiated BM-MSC (week 0) did not (Fig. 5a). Although both EVs and protein fractions positively stimulate WJ-MSC osteogenesis, the effect produced by the soluble protein fraction resulted in a greater outcome than that produced by EVs collected at the same differentiation stage. Based on this observation, the full CM collected from BM-MSC cultures after 1 week of in vitro osteogenic induction was also tested (Fig. 5b). As shown in Fig. 5b, the addition of CM from differentiating BM-MSC to WJ-MSC cultures resulted in higher osteogenesis than the addition of purified EVs or protein fractions separately. Furthermore, the fact that calcium depositions were clearly identified from the very first week indicated a powerful synergistic positive effect between EV and proteins secreted by BM-MSC in the progression along the osteogenic linage differentiation.

Fig. 5.

Fig. 5

Open in a new tab

Effect of BM-MSC-derived products on osteogenic commitment of WJ-MSC. a Representative images of AR staining in passage 4 WJ-MSC after 3 weeks of culture with ODM alone (top) or supplemented with either EV or protein fractions collected from undifferentiated BM-MSC (week 0) or BM-MSC cultures at week 1, 2 or 3 of osteogenic differentiation (bottom). b Representative images of AR staining in passage 4 WJ-MSC after 1, 2 or 3 weeks of culture with CM obtained from differentiating BM-MSC cultures at week 1. CM conditioned media, EV extracellular vesicles, ODM osteogenic differentiation media, SN supernatant. In all cases, scale bars: 100 μm

Discussion

The use of allogeneic MSC is promising for the treatment of bone-related conditions. In this context, some studies have suggested that master cell banks of WJ-MSC may offer advantages over the use of BM-MSC [20, 22]. However, to guarantee the success of WJ-MSC in situations where bone repair or bone regeneration is required, it is essential to demonstrate that osteogenic commitment is equally driven in both BM- and WJ-MSC.

In the present study, we have extensively characterised the osteogenic differentiation process of BM- and WJ-MSC in order to provide homogeneous data because, despite there are many reports in the field describing osteogenic properties of both cell lines, data sets are often incomplete and non-comparable due to heterogeneity in isolation and culture procedures.

In concordance with previous observations reported by other authors in the field [43, 44], our findings evidenced that WJ-MSC are less prone to differentiate into bone cells than BM-MSC. We thus aimed to comparatively analyse the molecular machinery associated with osteogenic differentiation in BM- and WJ-MSC since we found a marked delay in the osteogenic progression of WJ-MSC compared to BM-MSC. Results obtained by qRT-PCR confirmed that BM-MSC exhibit an osteogenic gene profile more similar to that of osteoblast and evidenced that MSX2, a TGFβ1-induced factor reported to promote cell proliferation and supress osteogenic differentiation by inhibiting DLX5-driven effects [36, 45–48], was overexpressed in WJ-MSC. This suggests that the balance between MSX2 and DLX5 expression could be critical in MSC, resulting in either a proliferating or differentiating outcome.

Trying to revert the scenario found in WJ-MSC, we then attempted to modulate TGFβ- and BMP-mediated signalling pathways by adding specific activators or inhibitors in order to repress MSX2 and/or to stimulate DLX5 expression. To this end, we used different combinations of chemical factors including (i) galunisertib, a receptor antagonist that specifically targets and binds TGFβRI [49]; (ii) BMP2, which has been reported to induce osteoblast differentiation by promoting DLX5 expression [33, 50] and (iii) tanshinone IIA, a phytochemical compound reported to enhance BMP signalling stimulation [51]. Neither the use of each molecule separately nor the combination of a repressing and activating agent resulted in an osteogenic output in WJ-MSC. However, agreeing with the results published by Heo and collaborators in umbilical cord blood MSC [52], the addition of tanshinone IIA to BMP2-induced cultures significantly increased calcium depositions in WJ-MSC after 3 weeks, thus matching WJ-MSC osteogenic behaviour to that of their BM-MSC counterparts.

Although systemic infusion of MSC has been shown to increase bone growth and repair in clinical trials [53–55], administered cells engraft poorly. In this line, previous in vivo studies carried out by our group in which ovine eGFP+ BM-MSC were infused in an ovine model of osteonecrosis of the femoral head demonstrated the presence of non-stained eGFP osteocytes in newly formed bone matrix, suggesting that contribution of MSC lies also in paracrine signalling that activate and recruit host osteoblasts to the bone repair areas [56]. Increasing evidence have shown that nanosized, membrane-encapsulated EVs are one of the most active MSCs’ secreted factors [25]. Indeed, EVs can serve as powerful tools for cell-free therapy due to precise multifunctional molecular cargoes [57, 58]. However, significant differences have been described in the content of EV purified from MSC cultures of different origins. In terms of miRNA profiles, BM-MSC-derived EVs have been described to present a miRNA cargo that is tightly related to MSC differentiation [59]. Furthermore, different profiles of miRNAs have also been reported depending on the differentiation stage of the secretory cell [60]. Here, we studied the differences in the protein content of EVs obtained from undifferentiated BM- and WJ-MSC. As a result, COL6A1, COL6A2, PCOLCE, COL12A1 and COL6A3 osteogenic markers were differentially overrepresented in BM-derived EVs compared to WJ-MSC EVs. Interestingly, COL6 and COL12 interactions have been reported to control and promote bone formation in early phases due to their role in the establishment of matrix bridges between adjacent cells when pre-osteoblasts establish cell-cell communication [61]. These observations prompted us to evaluate the effect of BM-MSC-derived EVs in the osteogenic differentiation of WJ-MSC. Additionally, the impact of the soluble protein fractions (eluted in the latter size exclusion chromatography (SEC) fractions) purified from BM-CM was also determined.

Both EV-rich and soluble protein fractions from differentiating BM-MSC cultures promote bone differentiation in WJ-MSC. On the contrary, the secretome of undifferentiated BM-MSC does not have an osteogenic effect. This fact matches the differences reported in the miRNA content of MSC-EVs depending on differentiation stages and explains, in part, the little differences found in the protein content of undifferentiated BM-MSC and WJ-MSC EVs. Remarkably, the use of unprocessed CM obtained from differentiating BM-MSC has a greater impact on osteogenic induction and produces not only an exacerbation on the mineralisation of the culture but also a shortening in the differentiation time. This suggests that EV- and protein-rich fractions from differentiating BM-MSC act by different and synergistic pathways, thus pointing out that BM-MSC and WJ-MSC therapeutic efficacy could be equivalent when administered within the bone microenvironment, where BM-MSC are present, and mitigating the need to overstimulate WJ-MSC osteogenesis ex vivo. This is particularly relevant due to the implications of WJ-MSC osteogenic priming in manufacturing development and clinical applications which include (i) prolonged cell cultures for ex vivo stimulation; (ii) difficulties of cell trypsinisation once the differentiation process is started; (iii) higher costs associated with the increment in time for cell culture and the use of additional GMP grade products; and (iv) possible clinical complications surrounding the use of priming compounds. Furthermore, the effect associated with the use of CM could be enhanced in vivo due to the immune response produced under pathophysiological conditions, which positively contributes to bone regeneration.

Conclusions

Despite their multipotentiality, the intrinsic molecular signature of WJ-MSC described here highly counteracts their osteogenic differentiation and thus their future application in cell-based therapies against orthopaedic conditions. However, our findings demonstrate that secreted factors in the CM from differentiating BM-MSC cultures greatly enhance WJ-MSC osteogenesis and suggest that intra-bony environment could be enough to guarantee WJ-MSC-promoted bone regeneration. This fact avoids the need either to overstimulate WJ-MSC osteogenesis ex vivo or to use genetically modified WJ-MSC. Therefore, although further research is required in order to evaluate the therapeutic benefit of WJ-MSC in the context of orthopaedic diseases, the use of GMP-grade master cell banks of WJ-MSC may be a valuable alternative to those of BM-MSC.

Supplementary information

13287_2019_1450_MOESM1_ESM.docx (400.3KB, docx)

Additional file 1 Immunophenotypic characterization of BM-MSC and WJ-MSC. Boxes represent median and 5-95 percentiles. N = 3 for each cell type.

13287_2019_1450_MOESM2_ESM.docx (372.1KB, docx)

Additional file 2. EV and protein fractions isolation and characterization. (A) Scheme of the methodological procedure followed for EV and protein isolation from BM-MSC and WJ-MSC conditioned media. CCM, concentrated conditioned media; CM, conditioned media; EV, extracellular vesicles; SEC, size exclusion chromatography; SN, cell culture supernatant. (B) Example of representative elution profile obtained for CD9 and CD63 EV markers quantification by bead-based flow cytometry (left axis) and for protein elution monitoring by absorption at 280 nm (right axis) in the different SEC fractions. MFI, mean fluorescence intensity. (C) Cryo-EM images confirming EVs presence in pooled EV fractions. Scale bar: 200 nm.

Acknowledgements

The authors would like to acknowledge Clémentine Mirabel and Blanca Reyes for the technical support and advice, and Dr. Kristel van Landuyt for critically reviewing the manuscript and providing helpful comments.

Abbreviations

ALP

Alkaline phosphatase

AR

Alizarin red

BM

Bone marrow

CM

Conditioned media

EV

Extracellular vesicle

FDR

False discovery rate

GMP

Good manufacturing practice

ISCT

International Society for Cell and Gene Therapy

MSC

Mesenchymal stromal cell

ODM

Osteogenic differentiation media

qRT-PCR

Quantitative real-time PCR

RT

Room temperature

SEC

Size exclusion chromatography

WJ

Wharton’s jelly

Authors’ contributions

RC-P, FEB, SR and JV conceived the study. RC-P, MM-T, AG-V and RR-M performed the experiments and analysed the data. RC-P wrote the manuscript. All authors revised the manuscript. All authors approved the final version of the manuscript.

Funding

Work in our laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788), Fundació la Marató de TV3 (expedient number: 122831), and ISCIII-REDinREN (RD16/0009 Feder Funds), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational programme (European Regional Development Fund) 2014-2020. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya). Our laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Groups (ref. 2017-SGR-719, 2017-SGR-301 and 2017-SGR-483).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding authors on request.

Ethics approval and consent to participate

Clinical grade BM-MSC were produced within the context of four clinical trials (EudraCT Nos. 2010-023998-18, 2010-023999-12, 2013-005025-23 and 2015005786-23). WJ-MSC were isolated from umbilical cord tissue collected within the Concordia Program (EudraCT No. 2015-005786-23). Appropriate donor informed consent for use in research was obtained in all cases.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Raquel Cabrera-Pérez, Phone: +34935573500, Email: rcabrera@bst.cat.

Joaquim Vives, Phone: +34935573500, Email: jvives@bst.cat.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13287-019-1450-3.

References

  • 1.Im G-I. Clinical use of stem cells in orthopaedics. Eur Cells Mater. 2017;33:183–196. doi: 10.22203/eCM.v033a14. [DOI] [PubMed] [Google Scholar]
  • 2.Sampson S, Botto-van Bemden A, Aufiero D. Stem cell therapies for treatment of cartilage and bone disorders: osteoarthritis, avascular necrosis, and non-union fractures. Regen Med. 2015;7(4):S26–S32. doi: 10.1016/j.pmrj.2015.01.023. [DOI] [PubMed] [Google Scholar]
  • 3.Naji Abderrahim, Eitoku Masamitsu, Favier Benoit, Deschaseaux Frédéric, Rouas-Freiss Nathalie, Suganuma Narufumi. Biological functions of mesenchymal stem cells and clinical implications. Cellular and Molecular Life Sciences. 2019;76(17):3323–3348. doi: 10.1007/s00018-019-03125-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Perez JR, Kouroupis D, Li DJ, Best TM, Kaplan L, Correa D. Tissue engineering and cell-based therapies for fractures and bone defects. Front Bioeng Biotechnol. 2018;6(July):1–23. doi: 10.3389/fbioe.2018.00105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gómez-Barrena E, Rosset P, Gebhard F, Hernigou P, Baldini N, Rouard H, et al. Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials. 2019;196:100–108. doi: 10.1016/j.biomaterials.2018.03.033. [DOI] [PubMed] [Google Scholar]
  • 6.Giannotti S, Trombi L, Bottai V, Ghilardi M, D’Alessandro D, Danti S, et al. Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessment. PLoS One. 2013;8(8):e73893. doi: 10.1371/journal.pone.0073893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Annamalai RT, Hong X, Schott NG, Tiruchinapally G, Levi B, Stegemann JP. Injectable osteogenic microtissues containing mesenchymal stromal cells conformally fill and repair critical-size defects. Biomaterials. 2019;208:32–44. doi: 10.1016/j.biomaterials.2019.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Prat S, Gallardo-Villares S, Vives M, Carreño A, Caminal M, Oliver-Vila I, et al. Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. J Tissue Eng Regen Med. 2018;12(1):e532–e540. doi: 10.1002/term.2323. [DOI] [PubMed] [Google Scholar]
  • 9.Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102(11):1319–1330. doi: 10.1161/CIRCRESAHA.108.175943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kretlow JD, Jin Y-Q, Liu W, Zhang WJ, Hong T-H, Zhou G, et al. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol. 2008;9(1):60–72. doi: 10.1186/1471-2121-9-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Saba-Choudhery M, Khan M, Mahmood R, Mehmood A, Khan SN, Riazuddin S. Bone marrow derived mesenchymal stem cells from aged mice have reduced wound healing, angiogenesis, proliferation and anti-apoptosis capabilities. Cell Biol Int. 2012;36(8):747–753. doi: 10.1042/CBI20110183. [DOI] [PubMed] [Google Scholar]
  • 12.Mendes SC, Tibbe JM, Veenhof M, Bakker K, Both S, Platenburg PP, et al. Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. Tissue Eng. 2002;8(6):911–920. doi: 10.1089/107632702320934010. [DOI] [PubMed] [Google Scholar]
  • 13.Baker N, Boyette LB, Tuan RS. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone. 2015;70:37–47. doi: 10.1016/j.bone.2014.10.014. [DOI] [PubMed] [Google Scholar]
  • 14.Karantalis V, Hernandez-Schulman I, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ Res. 2015;116(1):12–15. doi: 10.1161/CIRCRESAHA.114.305495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mirabel C, Puente-Massaguer E, Del Mazo-Barbara A, Reyes B, Morton P, Gòdia F, et al. Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products. J Transl Med. 2018;16(1):291–300. doi: 10.1186/s12967-018-1659-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Singh-Mohal J, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Curr Stem Cell Res Ther. 2012;7(2):103–109. doi: 10.2174/157488812799219027. [DOI] [PubMed] [Google Scholar]
  • 17.Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45(11):e54–e16. doi: 10.1038/emm.2013.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. [DOI] [PubMed] [Google Scholar]
  • 19.Guadix JA, Zugaza JL, Gálvez-Martín P. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. Med Clínica (English Ed) 2017;148(9):408–414. doi: 10.1016/j.medcle.2017.04.018. [DOI] [PubMed] [Google Scholar]
  • 20.Vives Joaquim, Mirabel Clémentine. Reference Module in Biomedical Sciences. 2018. Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications. [Google Scholar]
  • 21.Davies J, Walker J, Keating A. Concise review: Wharton’s jelly: the rich, but enigmatic source of mesenchymal stromal cells. Stem Cells Transl Med. 2017;6(7):1620–1630. doi: 10.1002/sctm.16-0492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Oliver-Vila I, Coca MI, Grau-Vorster M, Pujals-Fonts N, Caminal M, Casamayor-Genescà A, et al. Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton’s jelly. Cytotherapy. 2016;18(1):25–35. doi: 10.1016/j.jcyt.2015.10.001. [DOI] [PubMed] [Google Scholar]
  • 23.La Rocca G, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R. Human Wharton’s jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther. 2013;8:100–113. doi: 10.2174/1574888X11308010012. [DOI] [PubMed] [Google Scholar]
  • 24.Deuse T, Stubbendorf M, Tang-Quan K, Phillips N, Kay MA, Eiermann T, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011;20(5):655–67. A. doi: 10.3727/096368910X536473. [DOI] [PubMed] [Google Scholar]
  • 25.Monguió-Tortajada M, Roura S, Gálvez-Montón C, Pujal JM, Aran G, Sanjurjo L, et al. Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. Theranostics. 2017;7(2):270–284. doi: 10.7150/thno.16154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Monguió-Tortajada M, Roura S, Gálvez-Montón C, Franquesa M, Bayes-Genis A, Borràs FE. Mesenchymal stem cells induce expression of CD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo. Front Immunol. 2017;8:1577. doi: 10.3389/fimmu.2017.01577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rahman S, Akhtar N, Jamil HM, Banik RS, Asaduzzaman SM. TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation. 2015;3:15005. 10.1038/boneres.2015.5. [DOI] [PMC free article] [PubMed]
  • 28.Beederman M, Lamplot J, Nan G, Wang J, Liu X, Yin L, et al. BMP signaling in mesenchymal stem cell differentiation and bone formation. J Biomed Sci Eng. 2013;6(8A):32–52. doi: 10.4236/jbise.2013.68A1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Grafe Ingo, Alexander Stefanie, Peterson Jonathan R., Snider Taylor Nicholas, Levi Benjamin, Lee Brendan, Mishina Yuji. TGF-β Family Signaling in Mesenchymal Differentiation. Cold Spring Harbor Perspectives in Biology. 2017;10(5):a022202. doi: 10.1101/cshperspect.a022202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wu M, Chen G, Li YP. TGF-β and BMP signaling in osteoblast, skeletal development and bone formation, homeostasis and disease. Bone Res. 2016;4 10.1038/boneres.2016.9. [DOI] [PMC free article] [PubMed]
  • 31.Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor β superfamily during murine fracture healing. J Bone Miner Res. 2002;17(3):513–520. doi: 10.1359/jbmr.2002.17.3.513. [DOI] [PubMed] [Google Scholar]
  • 32.Mehrara B, Most D, Chang J, Bresnick S, Turk A, Schendel S, et al. Basic fibroblast growth factor and transforming growth factor β-1 expression in the developing dura mater correlates with calvarial bone formation. Plast Reconstr Surg. 1999;104(2):435–444. doi: 10.1097/00006534-199908000-00017. [DOI] [PubMed] [Google Scholar]
  • 33.Miyama K, Yamada G, Yamamoto TS, Takagi C, Miyado K, Sakai M, et al. A BMP-inducible gene, Dlx5, regulates osteoblast differentiation and mesoderm induction. Dev Biol. 1999;208(1):123–133. doi: 10.1006/dbio.1998.9197. [DOI] [PubMed] [Google Scholar]
  • 34.Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-β1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem. 2003;278(36):34387–34394. doi: 10.1074/jbc.M211386200. [DOI] [PubMed] [Google Scholar]
  • 35.Guerrero F, Herencia C, Almadén Y, Martínez-Moreno JM, Montes De Oca A, Rodriguez-Ortiz ME, et al. TGF-β prevents phosphate-induced osteogenesis through inhibition of BMP and Wnt/β-catenin pathways. PLoS One. 2014;9(2):1–10. doi: 10.1371/journal.pone.0089179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Galléa S, et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β1 on osteoblast differentiation. Bone. 2001;29(4):323–330. doi: 10.1016/S8756-3282(01)00580-4. [DOI] [PubMed] [Google Scholar]
  • 37.Codinach M, Blanco M, Ortega I, Lloret M, Reales L, Coca MI, et al. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells. Cytotherapy. 2016;18(9):1197–1208. doi: 10.1016/j.jcyt.2016.05.012. [DOI] [PubMed] [Google Scholar]
  • 38.Oliver-Vila I, Ramírez-Moncayo C, Grau-Vorster M, Marín-Gallén S, Caminal M, Vives J. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology. 2018;70:31–44. doi: 10.1007/s10616-017-0186-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Monguió‐Tortajada Marta, Morón‐Font Miriam, Gámez‐Valero Ana, Carreras‐Planella Laura, Borràs Francesc E., Franquesa Marcella. Extracellular‐Vesicle Isolation from Different Biological Fluids by Size‐Exclusion Chromatography. Current Protocols in Stem Cell Biology. 2019;49(1):e82. doi: 10.1002/cpsc.82. [DOI] [PubMed] [Google Scholar]
  • 40.Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, et al. EVpedia: a community web portal for extracellular vesicles research. Bioinformatics. 2015;31(6):933–939. doi: 10.1093/bioinformatics/btu741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics. 2009;9(21):4997–5000. doi: 10.1002/pmic.200900351. [DOI] [PubMed] [Google Scholar]
  • 42.Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012;10(12):8–12. doi: 10.1371/journal.pbio.1001450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hsieh J, Fu Y, Chang S, Tsuang Y, Wang H. Mesenchymal stem cells from bone marrow and Wharton’s jelly of umbilical cord. Stem Cells and Dev. 2010;19(12):1895–1910. doi: 10.1089/scd.2009.0485. [DOI] [PubMed] [Google Scholar]
  • 44.Batsali AK, Pontikoglou C, Koutroulakis D, Pavlaki KI, Damianaki A, Mavroudi I, et al. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton’s jelly and bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2017;8:102. doi: 10.1186/s13287-017-0555-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Hu G, Lee H, Price SM, Shen MM, Abate-Shen C. Msx homeobox genes inhibit differentiation through upregulation of cyclin D1. Development. 2001;128:2373–2384. doi: 10.1242/dev.128.12.2373. [DOI] [PubMed] [Google Scholar]
  • 46.Newberry EP, Latifi T, Towler DA. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. Biochemistry. 1998;37:16360–16368. doi: 10.1021/bi981878u. [DOI] [PubMed] [Google Scholar]
  • 47.Kim Y-J, Lee M-H, Wozney JM, Cho J-Y, Ryoo HM. Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by Dlx5 and repressed by Msx2. J Biol Chem. 2004;279(49):50773–50780. doi: 10.1074/jbc.M404145200. [DOI] [PubMed] [Google Scholar]
  • 48.Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. Genes Cells. 2001;6(10):851–856. doi: 10.1046/j.1365-2443.2001.00466.x. [DOI] [PubMed] [Google Scholar]
  • 49.Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget. 2018;9(6):6659–6677. doi: 10.18632/oncotarget.23795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Ulsamer A, Ortuño MJ, Ruiz S, Susperregui ARG, Osses N, Rosa JL, et al. BMP-2 induces osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem. 2008;283(7):3816–3826. doi: 10.1074/jbc.M704724200. [DOI] [PubMed] [Google Scholar]
  • 51.Kim HJ, Kim SH. Tanshinone IIA enhances BMP-2-stimulated commitment of C2C12 cells into osteoblasts via p38 activation. Amino Acids. 2010;39(5):1217–1226. doi: 10.1007/s00726-010-0557-8. [DOI] [PubMed] [Google Scholar]
  • 52.Heo JS, Lee SG, Kim HO. Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells. Int J Mol Med. 2017;40(5):1486–1494. doi: 10.3892/ijmm.2017.3142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Blanco JF, Villarón EM, Pescador D, Da Casa C, Gómez V, Redondo AM, et al. Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up. Stem Cell Res Ther. 2019;10(63):1–8. doi: 10.1186/s13287-019-1166-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Kaigler D, Pagni G, Ho Park C, Braun TM, Holman LA, Yi E, et al. Stem cell therapy for craniofacial bone regeneration: a randomized, controlled feasibility trial. Cell Transplant. 2013;22(5):767–777. doi: 10.3727/096368912X652968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, et al. Stem cell-based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study. Mol Ther. 2013;21(8):1631–1638. doi: 10.1038/mt.2013.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Caminal M, Vélez R, Rabanal RM, Vivas D, Batlle-Morera L, Aguirre M, et al. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. J Tissue Eng Regen Med. 2017;11(12):3408–3416. doi: 10.1002/term.2254. [DOI] [PubMed] [Google Scholar]
  • 57.Roura Santiago, Vives Joaquim. Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood. Metabolism. 2019;95:102–104. doi: 10.1016/j.metabol.2019.02.006. [DOI] [PubMed] [Google Scholar]
  • 58.Roura S, Bayes-Genis A. Toward standardization of mesenchymal stromal cell-derived extracellular vesicles for therapeutic use: a call for action. Proteomics. 2019;19:1800397. doi: 10.1002/pmic.201800397. [DOI] [PubMed] [Google Scholar]
  • 59.Zhou Y, Yamamoto Y, Ochiya T, Xiao Z, Itaya T. Distinct Mirna expression patterns of extracellular vesicles derived from 4 types of mesenchymal stem cells. J Stem Cell Res Ther. 2018;8:415. 10.4172/2157-7633.1000415.
  • 60.Wang X, Omar O, Vazirisani F, Thomsen P, Ekström K. Mesenchymal stem cell-derived exosomes have altered microRNA profiles and induce osteogenic differentiation depending on the stage of differentiation. PLoS One. 2018;13(2):e0193059. doi: 10.1371/journal.pone.0193059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Izu Y, Ezura Y, Koch M, Birk DE, Noda M. Collagens VI and XII form complexes mediating osteoblast interactions during osteogenesis. Cell Tissue Res. 2016;364(3):623–635. doi: 10.1007/s00441-015-2345-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13287_2019_1450_MOESM1_ESM.docx (400.3KB, docx)

Additional file 1 Immunophenotypic characterization of BM-MSC and WJ-MSC. Boxes represent median and 5-95 percentiles. N = 3 for each cell type.

13287_2019_1450_MOESM2_ESM.docx (372.1KB, docx)

Additional file 2. EV and protein fractions isolation and characterization. (A) Scheme of the methodological procedure followed for EV and protein isolation from BM-MSC and WJ-MSC conditioned media. CCM, concentrated conditioned media; CM, conditioned media; EV, extracellular vesicles; SEC, size exclusion chromatography; SN, cell culture supernatant. (B) Example of representative elution profile obtained for CD9 and CD63 EV markers quantification by bead-based flow cytometry (left axis) and for protein elution monitoring by absorption at 280 nm (right axis) in the different SEC fractions. MFI, mean fluorescence intensity. (C) Cryo-EM images confirming EVs presence in pooled EV fractions. Scale bar: 200 nm.

Data Availability Statement

The datasets used and/or analysed during the current study are available from the corresponding authors on request.

Articles from Stem Cell Research & Therapy are provided here courtesy of BMC

RESOURCES